02.12.2010 • News

Merck Set to Buy Biotech Firm SmartCells

U.S. pharmaceutical company Merck & Co. is set to buy SmartCells Inc, a privately held biotechnology firm in the early stages of developing a new diabetes drug, the Wall Street Journal reported.

The deal for SmartCells would exceed $500 million if various milestones for development, regulatory approval and sales were met and could be announced as early as Thursday, a person familiar with the matter told the Journal.

A SmartCells deal would expand Merck's treatment offerings for diabetes. It already has two top-selling drugs for Type 2 diabetics in its portfolio.

Merck could not be reached for comment.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.